Infections during novel myeloma therapies
- Author(s)
- Liu, AJ; Slavin, MA; Harrison, SJ; Teh, BW;
- Details
- Publication Year 2025-03,Volume 66,Issue #3,Page 420-432
- Journal Title
- Leukemia & Lymphoma
- Publication Type
- Review
- Abstract
- New generation therapies such as bispecific antibodies (BsAb), chimeric antigen receptor T-cell therapy (CAR T) and antibody-drug conjugates (ADC) have revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM). However, there is emerging evidence of increased infection risk associated with these treatments in clinical trials and observational settings. This infection risk may be mediated by on-target, off-tumor side effects such as cytokine release syndrome, hypogammaglobulinaemia and cytopenias, disease-related humoral impairment and the consequences of multiple previous lines of treatment. While bacterial and viral pathogens predominate, reactivation of latent infection and opportunistic infections also warrant attention. This review characterizes the epidemiology of infections associated with novel therapies for RRMM to guide prophylaxis and antimicrobial prescribing in this patient population and highlights future areas of focus to inform ongoing infection prevention strategies.
- Keywords
- Humans; *Multiple Myeloma/therapy/epidemiology/complications; Infections/etiology/epidemiology; Immunotherapy, Adoptive/adverse effects/methods; Opportunistic Infections/epidemiology/immunology/etiology; Antibodies, Bispecific/therapeutic use/adverse effects; Immunoconjugates/therapeutic use/adverse effects; CAR T-cell therapy; Multiple myeloma; antimicrobial prophylaxis; bispecifics; vaccination
- Department(s)
- Infectious Diseases; Medical Oncology; Haematology
- Publisher's Version
- https://doi.org/10.1080/10428194.2024.2428819
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-12-17 03:06:45
Last Modified: 2025-03-21 02:55:13